Neuroblastoma Treatment Market By Drug 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Neuroblastoma Treatment Market
Neuroblastoma Treatment Market: By Drug (Xalkori, Clafen, Vincasar PFS) By Treatment (Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy) & Geography - Forecast(2018 - 2023)
Report Code : HCR 0302
Updated Date: 15 May, 2018  

  • Report Description
  • Table of Contents
  • Tables And Figures
  • Customization Options
1. Neuroblastoma Treatment– Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Neuroblastoma Treatment– Market Forces
   4.1. Drivers
      4.1.1. Rising cases of cancer in infants due to life style related health impacts
   4.2. Opportunities
   4.3. Challenges
      4.3.1. Lower awareness in the developing nations
   4.4. Porter’s Five Forces Analysis
      4.4.1. Bargaining Power of Suppliers
      4.4.2. Bargaining Power of Buyers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitutes
      4.4.5. Degree of Competition
5. Neuroblastoma Treatment– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Neuroblastoma Treatment Market, By Drug
   6.1. Xalkori (crizotinib)
   6.2.  Adriamycin PFS (Doxorubicin Hydrochloride)
   6.3. Clafen (Cyclophosphamide)
   6.4. Vincasar PFS (Vincristine Sulfate)
   6.5. Others
7. Neuroblastoma Treatment Market, By Treatment
   7.1. Surgery
   7.2. Chemotherapy
   7.3. High-dose chemotherapy with stem cell support
   7.4. Monoclonal antibody treatment
   7.5. Radiotherapy
   7.6. Others
8. Neuroblastoma Treatment Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Neuroblastoma Treatment– Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Top 10 Companies)
   10.1. Seattle Children’s
   10.2. Cure Search
   10.3. Texas Children’s
   10.4. NANTGE Healthcare
   10.5. Pfizer Inc.
   10.6. GL Pharm Tech Corporation
   10.7. Hôpitaux de ParisOthers
   10.8. Erasmus Medical Center
   10.9. Assistance Publique - Hopitaux de Paris
   10.10. Texas Neurofibromatosis Foundation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of expert Insights
   11.6. Disclaimer
Neuroblastoma is the most common type of cancer found in infants. Neuroblastoma is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. This cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is classified as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. Neuroblastoma is a cancer which starts in primitive nerve cells. It rarely occurs after age around 10 years. According to America Cancer Society, neuroblastoma accounts for over 7% of the total cancer cases in age group of 0 to 14 years of age. Some of the most common symptoms of the neuroblastoma are firm mass in the abdomen, enlarged stomach, weight, anemia, crankiness, fever, bone pain, bulging eyes, dark circles around the eyes, weakness, and high blood pressure

Neuroblastoma Treatment Market

North America held substantial revenue share of the overall oxygen therapy market The increasing number of product approvals and high R&D investments are the key growth drivers responsible for the largest share of the market in this region. It is followed by Europe in terms of revenue share owing to the presence of favorable government initiatives for improving respiratory care, such as European Committee for Hyperbaric Medicine (ECHM), involved in promoting awareness pertaining to the treatment.This report on global Neuroblastoma Treatmentis segmented on the basis of Neuroblastoma Treatment application, end-use industries using Neuroblastoma Treatment for wide range of end-use applications and market size in various geographical regions.

This report identifies the Neuroblastoma Treatment market size in for the year 2016-2021, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Neuroblastoma Treatment market.

This report segments global neuroblastoma market on the basis of type, procedures, and regional market as follows:
  • On the basis of treatment categories of Neuroblastoma Treatment, this report is segmented into five major treatment. Some of the major treatment covered  in this report are as follows: Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy and Others
  •  On the basis of drug categories of Neuroblastoma Treatment, this report is segmented into five major drugs. Some of the major drugs covered  in this report are as follows: Xalkori (crizotinib),  Adriamycin PFS (Doxorubicin Hydrochloride), Clafen (Cyclophosphamide), Vincasar PFS (Vincristine Sulfate) and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Neuroblastoma Treatment in each of the region.

This report identifies all the major companies operating in the global Neuroblastoma Treatment market. Some of the major companies’ profiles in detail are as follows:
  • Seattle Children’s
  • Cure Search
  • Texas Children’s
  • NANTGE Healthcare
  • Others
List of Tables:

Table 1: Neuroblastoma Treatment Market Overview 2017-2023
Table 2: Neuroblastoma Treatment Market Leader Analysis 2017-2018 (US$)
Table 3: Neuroblastoma Treatment Market Product Analysis 2017-2018 (US$)
Table 4: Neuroblastoma Treatment Market End User Analysis 2017-2018 (US$)
Table 5: Neuroblastoma Treatment Market Patent Analysis 2013-2018* (US$)
Table 6: Neuroblastoma Treatment Market Financial Analysis 2017-2018 (US$)
Table 7: Neuroblastoma Treatment Market Driver Analysis 2017-2018 (US$)
Table 8: Neuroblastoma Treatment Market Challenges Analysis 2017-2018 (US$)
Table 9: Neuroblastoma Treatment Market Constraint Analysis 2017-2018 (US$)
Table 10: Neuroblastoma Treatment Market Supplier Bargaining Power Analysis 2017-2018 (US$)
Table 11: Neuroblastoma Treatment Market Buyer Bargaining Power Analysis 2017-2018 (US$)
Table 12: Neuroblastoma Treatment Market Threat of Substitutes Analysis 2017-2018 (US$)
Table 13: Neuroblastoma Treatment Market Threat of New Entrants Analysis 2017-2018 (US$)
Table 14: Neuroblastoma Treatment Market Degree of Competition Analysis 2017-2018 (US$)
Table 15: Neuroblastoma Treatment Market Value Chain Analysis 2017-2018 (US$)
Table 16: Neuroblastoma Treatment Market Pricing Analysis 2018-2023 (US$)
Table 17: Neuroblastoma Treatment Market Opportunities Analysis 2018-2023 (US$)
Table 18: Neuroblastoma Treatment Market Product Life Cycle Analysis 2018-2023 (US$)
Table 19: Neuroblastoma Treatment Market Supplier Analysis 2017-2018 (US$)
Table 20: Neuroblastoma Treatment Market Distributor Analysis 2017-2018 (US$)
Table 21: Neuroblastoma Treatment Market Trend Analysis 2017-2018 (US$)
Table 22: Neuroblastoma Treatment Market Size 2017 (US$)
Table 23: Neuroblastoma Treatment Market Forecast Analysis 2018-2023 (US$)
Table 24: Neuroblastoma Treatment Market Sales Forecast Analysis 2018-2023 (Units)
Table 25: Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 26: Neuroblastoma Treatment Market By Drug, Revenue & Volume, By Xalkori, 2018-2023 ($)
Table 27: Neuroblastoma Treatment Market By Drug, Revenue & Volume, By Adriamycin PFS, 2018-2023 ($)
Table 28: Neuroblastoma Treatment Market By Drug, Revenue & Volume, By Clafen, 2018-2023 ($)
Table 29: Neuroblastoma Treatment Market By Drug, Revenue & Volume, By Vincasar PFS, 2018-2023 ($)
Table 30: Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 31: Neuroblastoma Treatment Market By Technology, Revenue & Volume, By Surgery, 2018-2023 ($)
Table 32: Neuroblastoma Treatment Market By Technology, Revenue & Volume, By Chemotherapy, 2018-2023 ($)
Table 33: Neuroblastoma Treatment Market By Technology, Revenue & Volume, By High-dose chemotherapy with stem cell support, 2018-2023 ($)
Table 34: Neuroblastoma Treatment Market By Technology, Revenue & Volume, By Monoclonal antibody treatment, 2018-2023 ($)
Table 35: " Neuroblastoma Treatment Market By Technology, Revenue & Volume, By Radiotherapy, 2018-2023 ($)"
Table 36: North America Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 37: North America Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 38: South america Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 39: South america Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 40: Europe Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 41: Europe Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 42: APAC Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 43: APAC Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 44: Middle East & Africa Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 45: Middle East & Africa Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 46: Russia Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 47: Russia Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 48: Israel Neuroblastoma Treatment Market, Revenue & Volume, By Drug, 2018-2023 ($)
Table 49: Israel Neuroblastoma Treatment Market, Revenue & Volume, By Technology, 2018-2023 ($)
Table 50: Top Companies 2017 (US$) Neuroblastoma Treatment Market, Revenue & Volume
Table 51: Product Launch 2017-2018 Neuroblastoma Treatment Market, Revenue & Volume
Table 52: Mergers & Acquistions 2017-2018 Neuroblastoma Treatment Market, Revenue & Volume


List of Figures:

Figure 1: Overview of Neuroblastoma Treatment Market 2017-2023
Figure 2: Market Share Analysis for Neuroblastoma Treatment Market 2017 (US$)
Figure 3: Product Comparison in Neuroblastoma Treatment Market 2017-2018 (US$)
Figure 4: End User Profile for Neuroblastoma Treatment Market 2017-2018 (US$)
Figure 5: Patent Application and Grant in Neuroblastoma Treatment Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Neuroblastoma Treatment Market 2017-2018 (US$)
Figure 7: Market Entry Strategy in Neuroblastoma Treatment Market 2017-2018
Figure 8: Ecosystem Analysis in Neuroblastoma Treatment Market 2017
Figure 9: Average Selling Price in Neuroblastoma Treatment Market 2017-2023
Figure 10: Top Opportunites in Neuroblastoma Treatment Market 2017-2018
Figure 11: Market Life Cycle Analysis in Neuroblastoma Treatment Market Market Life Cycle Analysis in 3D Printing
Figure 12: GlobalBy DrugNeuroblastoma Treatment Market Revenue, 2018-2023 ($)
Figure 13: GlobalBy TechnologyNeuroblastoma Treatment Market Revenue, 2018-2023 ($)
Figure 14: Global Neuroblastoma Treatment Market - By Geography
Figure 15: Global Neuroblastoma Treatment Market Value & Volume, By Geography, 2018-2023 ($) 
Figure 16: Global Neuroblastoma Treatment Market CAGR, By Geography, 2018-2023 (%)
Figure 17: North America Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 18: US Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 19: US GDP and Population, 2017-2018 ($)
Figure 20: US GDP – Composition of 2017, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2017-2018 ($)
Figure 22: Canada Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 23: Canada GDP and Population, 2017-2018 ($)
Figure 24: Canada GDP – Composition of 2017, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2017-2018 ($)
Figure 26: Mexico Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 27: Mexico GDP and Population, 2017-2018 ($)
Figure 28: Mexico GDP – Composition of 2017, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2017-2018 ($)
Figure 30: South America Neuroblastoma Treatment Market South America 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 31: Brazil Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 32: Brazil GDP and Population, 2017-2018 ($)
Figure 33: Brazil GDP – Composition of 2017, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2017-2018 ($)
Figure 35: Venezuela Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 36: Venezuela GDP and Population, 2017-2018 ($)
Figure 37: Venezuela GDP – Composition of 2017, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2017-2018 ($)
Figure 39: Argentina Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 40: Argentina GDP and Population, 2017-2018 ($)
Figure 41: Argentina GDP – Composition of 2017, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2017-2018 ($)
Figure 43: Ecuador Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 44: Ecuador GDP and Population, 2017-2018 ($)
Figure 45: Ecuador GDP – Composition of 2017, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2017-2018 ($)
Figure 47: Peru Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 48: Peru GDP and Population, 2017-2018 ($)
Figure 49: Peru GDP – Composition of 2017, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2017-2018 ($)
Figure 51: Colombia Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 52: Colombia GDP and Population, 2017-2018 ($)
Figure 53: Colombia GDP – Composition of 2017, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2017-2018 ($)
Figure 55: Costa Rica Neuroblastoma Treatment Market Costa Rica 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 56: Costa Rica GDP and Population, 2017-2018 ($)
Figure 57: Costa Rica GDP – Composition of 2017, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2017-2018 ($)
Figure 59: Europe Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 60: U.K Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 61: U.K GDP and Population, 2017-2018 ($)
Figure 62: U.K GDP – Composition of 2017, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2017-2018 ($)
Figure 64: Germany Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 65: Germany GDP and Population, 2017-2018 ($)
Figure 66: Germany GDP – Composition of 2017, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2017-2018 ($)
Figure 68: Italy Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 69: Italy GDP and Population, 2017-2018 ($)
Figure 70: Italy GDP – Composition of 2017, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2017-2018 ($)
Figure 72: France Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 73: France GDP and Population, 2017-2018 ($)
Figure 74: France GDP – Composition of 2017, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2017-2018 ($)
Figure 76: Netherlands Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 77: Netherlands GDP and Population, 2017-2018 ($)
Figure 78: Netherlands GDP – Composition of 2017, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2017-2018 ($)
Figure 80: Belgium Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 81: Belgium GDP and Population, 2017-2018 ($)
Figure 82: Belgium GDP – Composition of 2017, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2017-2018 ($)
Figure 84: Spain Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 85: Spain GDP and Population, 2017-2018 ($)
Figure 86: Spain GDP – Composition of 2017, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2017-2018 ($)
Figure 88: Denmark Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 89: Denmark GDP and Population, 2017-2018 ($)
Figure 90: Denmark GDP – Composition of 2017, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2017-2018 ($)
Figure 92: APAC Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 93: China Neuroblastoma Treatment Market Value & Volume, 2018-2023
Figure 94: China GDP and Population, 2017-2018 ($)
Figure 95: China GDP – Composition of 2017, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2017-2018 ($)Neuroblastoma Treatment Market China Export and Import Value & Volume, 2017-2018 ($)
Figure 97: Australia Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 98: Australia GDP and Population, 2017-2018 ($)
Figure 99: Australia GDP – Composition of 2017, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2017-2018 ($)
Figure 101: South Korea Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 102: South Korea GDP and Population, 2017-2018 ($)
Figure 103: South Korea GDP – Composition of 2017, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2017-2018 ($)
Figure 105: India Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 106: India GDP and Population, 2017-2018 ($)
Figure 107: India GDP – Composition of 2017, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2017-2018 ($)
Figure 109: Taiwan Neuroblastoma Treatment Market Taiwan 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 110: Taiwan GDP and Population, 2017-2018 ($)
Figure 111: Taiwan GDP – Composition of 2017, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2017-2018 ($)
Figure 113: Malaysia Neuroblastoma Treatment Market Malaysia 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 114: Malaysia GDP and Population, 2017-2018 ($)
Figure 115: Malaysia GDP – Composition of 2017, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2017-2018 ($)
Figure 117: Hong Kong Neuroblastoma Treatment Market Hong Kong 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 118: Hong Kong GDP and Population, 2017-2018 ($)
Figure 119: Hong Kong GDP – Composition of 2017, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2017-2018 ($)
Figure 121: Middle East & Africa Neuroblastoma Treatment Market Middle East & Africa 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 122: Russia Neuroblastoma Treatment Market Russia 3D Printing Market Value & Volume, 2018-2023 ($)
Figure 123: Russia GDP and Population, 2017-2018 ($)
Figure 124: Russia GDP – Composition of 2017, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2017-2018 ($)
Figure 126: Israel Neuroblastoma Treatment Market Value & Volume, 2018-2023 ($)
Figure 127: Israel GDP and Population, 2017-2018 ($)
Figure 128: Israel GDP – Composition of 2017, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2017-2018 ($)
Figure 130: Entropy Share, By Strategies, 2017-2018* (%)Neuroblastoma Treatment Market
Figure 131: Developments, 2017-2018*Neuroblastoma Treatment Market
Figure 132: Company 1 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 133: Company 1 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 134: Company 1 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 135: Company 2 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 136: Company 2 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 137: Company 2 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 138: Company 3 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 139: Company 3 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 140: Company 3 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 141: Company 4 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 142: Company 4 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 143: Company 4 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 144: Company 5 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 145: Company 5 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 146: Company 5 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 147: Company 6 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 148: Company 6 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 149: Company 6 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 150: Company 7 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 151: Company 7 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 152: Company 7 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 153: Company 8 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 154: Company 8 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 155: Company 8 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 156: Company 9 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 157: Company 9 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 158: Company 9 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 159: Company 10 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 160: Company 10 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 161: Company 10 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 162: Company 11 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 163: Company 11 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 164: Company 11 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 165: Company 12 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 166: Company 12 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 167: Company 12 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 168: Company 13 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 169: Company 13 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 170: Company 13 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 171: Company 14 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 172: Company 14 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 173: Company 14 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Figure 174: Company 15 Neuroblastoma Treatment Market Net Revenue, By Years, 2017-2018* ($)
Figure 175: Company 15 Neuroblastoma Treatment Market Net Revenue Share, By Business segments, 2017 (%)
Figure 176: Company 15 Neuroblastoma Treatment Market Net Sales Share, By Geography, 2017 (%)
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll